Payment overview · 2025
General Payments
$327.81
12 reported records · 5 companies
Healthcare provider profile · identity verified
Robert Thomas Dewar
Allopathic & Osteopathic Physicians|Internal Medicine · DALLAS, TX · NPI 1235592429
Verified facts
What the public records show
CMS Open Payments records show Robert Thomas Dewar received $327.81 in general payments during 2025 across 12 reported records.
Novo Nordisk Inc accounted for 37.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Myrbetriq by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Biktarvy by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $124.34 | 37.9% | 8 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $123.82 | 37.8% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $43.11 | 13.2% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $22.53 | 6.9% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $14.01 | 4.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $327.81 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $123.82 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $79.31 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $79.31 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $45.03 | 3 | 2025 |
Source payment records
|
|||||
| APOLLO ESG System Normalized: apollo esg system |
Device | Boston Scientific Corporation | $43.11 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $14.01 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 48 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 357 | 112 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 208 | 61 |
| Amlodipine Besylate | Amlodipine Besylate | 195 | 61 |
| Lisinopril | Lisinopril | 145 | 41 |
| Pantoprazole Sodium | Pantoprazole Sodium | 138 | 44 |
| Levothyroxine Sodium | Levothyroxine Sodium | 133 | 41 |
| Losartan Potassium | Losartan Potassium | 116 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 111 | 32 |
| Gabapentin | Gabapentin | 97 | 39 |
| Carvedilol | Carvedilol | 92 | 28 |
| Metformin Hcl | Metformin Hcl | 90 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 89 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 88 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 78 | 20 |
| Simvastatin | Simvastatin | 73 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 67 | 12 |
| Sertraline Hcl | Sertraline Hcl | 66 | 20 |
| Omeprazole | Omeprazole | 61 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 60 | 16 |
| Alendronate Sodium | Alendronate Sodium | 58 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 58 | 19 |
| Metformin Hcl Er | Metformin Hcl | 58 | 15 |
| Spironolactone | Spironolactone | 57 | 16 |
| Trazodone Hcl | Trazodone Hcl | 53 | 19 |
| Alprazolam | Alprazolam | 51 | 11 |
| Ezetimibe | Ezetimibe | 51 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 50 | 17 |
| Allopurinol | Allopurinol | 49 | 14 |
| Ozempic | Semaglutide | 48 | suppressed |
| Bupropion Xl | Bupropion Hcl | 47 | 14 |
| Furosemide | Furosemide | 47 | 19 |
| Montelukast Sodium | Montelukast Sodium | 46 | 17 |
| Eliquis | Apixaban | 45 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 43 | 12 |
| Jardiance | Empagliflozin | 42 | 12 |
| Clonazepam | Clonazepam | 41 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 38 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 36 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 35 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 32 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 30 | 11 |
| Eszopiclone | Eszopiclone | 27 | suppressed |
| Pregabalin | Pregabalin | 27 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 27 | suppressed |
| Mounjaro | Tirzepatide | 26 | suppressed |
| Valsartan | Valsartan | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Meloxicam | Meloxicam | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | suppressed |
| Potassium Chloride | Potassium Chloride | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 21 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Felodipine Er | Felodipine | 16 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Prednisone | Prednisone | 14 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $327.81 · 12 records | Novo Nordisk Inc | APOLLO ESG System, APRETUDE, Ozempic, Rybelsus, Veozah, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error